The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series ; Первый опыт применения офатумумаба для лечения педиатрического рассеянного склероза в реальной российской клинической практике. Серия случаев

Συγγραφείς: E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko, Е. Д Кузьминых, В. М. Лебедев, В. Е. Сенченко, М. С. Черепянский, В. А. Гончар, Д. С. Коробко

Συνεισφορές: The article is sponsored by Novartis., Статья спонсируется компанией «Новартис»

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 17, No 1 (2025); 72-77 ; Неврология, нейропсихиатрия, психосоматика; Vol 17, No 1 (2025); 72-77 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2025-1

Θεματικοί όροι: анти-CD20-терапия, pediatric multiple sclerosis, multiple sclerosis, anti-CD20 monoclonal antibody, anti-CD20 therapy, педиатрический рассеянный склероз, рассеянный склероз, анти-CD20 моноклональные антитела

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2450/1776; Ghezzi A. Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach. Neurol Ther. 2024 Aug;13(4):949-63. doi:10.1007/s40120-024-00633-6. Epub 2024 Jun 1.; Jeong A, Oleske DM, Holman J. Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature. J Child Neurol. 2019 Oct;34(12):705- 12. doi:10.1177/0883073819845827. Epub 2019 Jun 11.; Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010 May;9(5):520-32. doi:10.1016/S1474-4422(10)70064-8; Клинические рекомендации «Рассеянный склероз» 2022. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/739_1 (дата обращения 20.08.2024).; Ghezzi A, Amato MP, Makhani N, et al. Pediatric multiple sclerosis: Conventional first-line treatment and general management. Neurology. 2016 Aug 30;87(9 Suppl 2):S97- S102. doi:10.1212/WNL.0000000000002823. Erratum in: Neurology. 2016 Nov 8;87(19):2068. doi:10.1212/WNL.0000000000003369; Benallegue N, Rollot F, Wiertlewski S, et al; OFSEP (Observatoire Francais de la Sclerose en Plaques) Investigators. Highly Effective Therapies as First-Line Treatment for PediatricOnset Multiple Sclerosis. JAMA Neurol. 2024 Mar 1;81(3):273-82. doi:10.1001/jamaneurol.2023.5566; Yearwood C, Wilbur C. Trends in the Epidemiology and Treatment of Pediatric-Onset Multiple Sclerosis in Alberta, Canada. J Child Neurol. 2023 Apr;38(5):321-8. doi:10.1177/08830738231176588; Pröbstel AK, Hauser SL. Multiple Sclerosis: B Cells Take Center Stage. J Neuroophthalmol. 2018 Jun;38(2):251-8. doi:10.1097/WNO.0000000000000642; Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of antiCD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024 Apr;271(4):1515-35. doi:10.1007/s00415-023-12007-3; Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019 Mar 14;7(1):20. doi:10.3390/biomedicines7010020; Mayrhofer P, Kunert R. Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. Hum Antibodies. 2019;27(1):37-51. doi:10.3233/HAB-180347; Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064. doi:10.3389/fimmu.2022.814064; Инструкция по применению лекарственного препарата Бонспри® (ОХЛП) ЛП-№(001332)-(РГ-RU)-251022. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7979032db214-4fa5-b9f2-f1731148f509 (дата обращения 20.11.2024).; Skataric M, Savelieva M, Pigeolet E, Leppert D. Ofatumumab Dose Selection in Pediatric Population with Relapsing Multiple Sclerosis. Abstract Т-090 for the Ninth American Conference on Pharmacometrics (ACoP9). J Pharmacokinet Pharmacodyn. 2018;45(Suppl 1):3-134. doi:10.1007/s10928-018-9606-9; ClinicalTrials.gov Identifier: NCT04926818. Available at: https://clinicaltrials.gov/ct2/show/NCT04926818; Gärtner J, Deiva K, Graves J, et al. Innovative Phase 3 NEOS Study Design Evaluating Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Paediatric Multiple Sclerosis. Poster 102. Poster presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 13–15 October 2021. Available at: https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2021/posters/P102_E CTRIMS2021.pdf (accessed 20.09.2024).; National Multiple Sclerosis Society Pediatric MS. Available at: https://www.nationalmssociety.org/For-Professionals/ClinicalCare/Managing-MS/Pediatric-MS; Margoni M, Rinaldi F, Perini P, Gallo P. Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities. Front Neurol. 2021 May 17;12:676095. doi:10.3389/fneur.2021.676095; Проект Клинических рекомендаций «Рассеянный склероз» от 2024 (МАВРС). Доступно по ссылке: https://mapcms.ru/projects/recommendations/proekty-klinicheskikhrekomendatsiy/ (дата обращения 20.08.2024).; Maillart E, Renaldo F, Papeix C, et al. Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 25;7(3):e683. doi:10.1212%2FNXI.0000000000000683; Sedani S, Absoud M, Milford D, et al. Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica. P675. Mult Scler J. 2012;18:(S4):279-508. doi:10.1177/1352458512459021; Gou B, Yang P, Feng J, et al. The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab. J Neuroimmunol. 2023 Mar 15;376:578035. doi:10.1016/j.jneuroim.2023.578035; Hiya S, Yoshimura H, Kawamoto M. Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoproteinimmunoglobulin G-associated disease (MOGAD). eNeurologicalSci. 2023 Apr 6;31:100461. doi:10.1007/s10928-018-9606-9; Bar-Or A, Wiendl H, Montalban X, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28(6):910-24. doi:10.1177/13524585211044479; Hauser SL, Bar-Or A, Cohen JA, et al.; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-57. doi:10.1056/NEJMoa1917246.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2450
https://doi.org/10.14412/2074-2711-2025-1-72-77